STORM-PE: Data driving change in PE treatment with CAVT
Acute intermediate- or high-risk pulmonary embolism (PE) represents one of the most severe manifestations of venous thromboembolic disease. Despite advances in treatment, early mortality remains high in patients with hemodynamic instability, and intermediate-risk PE still carries a 30-day mortality of 3–15%. A major contributor to poor outcomes is the right ventricular (RV) strain, present in over 25% of PE patients and associated with a more than two-fold increase in mortality, even in less severe cases.
The current standard of care (SOC) is therapeutic anticoagulation (AC). Additionally, reperfusion treatment aimed to immediately dissolute the thrombus is indicated as a frontline and life-saving option in high-risk PE, and as a rescue treatment in intermediate-risk PE if clinical and hemodynamic decompensation occurs despite adequately dosed AC treatment.
In recent years, endovascular therapy has emerged as a promising alternative. These catheter-based technologies aim to rapidly reduce thrombus burden, relieve RV strain, restore pulmonary perfusion, and lower early mortality risk.*
STORM-PE is the landmark trial with results shared at TCT 2025 showing superiority over anticoagulation with the use of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy (CAVT). CAVT demonstrated superior improvement in right heart strain and functional outcomes compared to patients treated with AC alone.**
This webinar will provide a focused analysis of latest clinical evidence supporting catheter-based therapy for intermediate-high-risk PE, with a spotlight on technical considerations and procedural workflow of computer assisted vacuum thrombectomy through real-life case examples.
P. Rosovsky, SV Konstantinides, JM Moriarty, et al. A prospective, multicenter, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus computer assisted vacuum thrombectomy for the treatment of intermediate-high-risk acute pulmonary embolism: Rationale and design of the STORM-PE study. Am Heart J. 2025; 288:1-14. DOI:10.1016/j.ahj.2025.03.018
Lookstein R, Konstantinides SV, Weinberg I, et al. Randomized controlled trial of mechanical thrombectomy with anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism: primary outcomes from the STORM-PE trial. 2025;[Published online ahead of print]. doi:10.1161/CIRCULATIONAHA.125.077232.
Learning objectives
By the end of this webinar, participants will be able to:
- Understand the evolution of PE treatment over the past decade and the role of technological innovation in improving patient care.
- Explain the rationale for conducting STORM-PE as the first RCT in aspiration thrombectomy vs the SOC, including key aspects of its design.
- Identify and interpret the primary and secondary endpoints of STORM-PE and their clinical significance.
- Discuss the implications of STORM-PE findings for current PE treatment strategies and decision-making.
- Apply evidence to practice through real-world case examples.
Programme
Introduction to Pulmonary embolism treatment
Prof. Bernhard Gebauer (Berlin/DE)
Why STORM-PE was needed: The study design
Prof. Stavros Konstantinides (Mainz/DE)
STORM-PE: First RCT in Aspiration Thrombectomy vs SOC
TBD
Panel discussion
From evidence into action: CAVT in practice
Dr. Narayan Karunanithy (London/GB)
Panel discussion
Faculty
Prof. Bernhard Gebauer (Berlin/DE)
Dr. Narayan Karunanithy (London/GB)
Prof. Stavros Konstantinides (Mainz/DE)
Join free of charge!
Access to this webinar is available free of charge to all interested parties. All you need is your CIRSE login details. Don’t have a CIRSE account yet? Not to worry! It only takes two minutes to set up a new account which will enable you to register.
This sponsored webinar is brought to you by Penumbra. Sponsored webinars are developed by a corporate partner and organised with the support of CIRSE.